These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

762 related articles for article (PubMed ID: 32362349)

  • 1. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
    Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
    Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
    Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
    Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
    Nafee T; Gibson CM; Yee MK; Alkhalfan F; Chi G; Travis R; Mir M; Kalayci A; Jafarizade M; Ganti A; Kazmi SH; Ghaffarpasand E; Pitliya A; Datta S; Sharfaei S; Alihashemi M; Elsaiey A; Qamar I; Jahansouz M; Talib U; Kahe F; Habibi S; Abdelwahed M; Tariq F; Kaur M; Younes A; Walia SS; Singh A; Dildar SM; Afzal MK; Kerneis M
    Expert Rev Cardiovasc Ther; 2018 Nov; 16(11):845-855. PubMed ID: 30296387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era.
    MacDougall K; Spyropoulos AC
    Semin Respir Crit Care Med; 2021 Apr; 42(2):308-315. PubMed ID: 33548931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
    J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.
    Laskier V; Guy H; Fisher M; Neuman WR; Bucior I; Cohen AT; Ren S
    J Med Econ; 2019 Oct; 22(10):1063-1072. PubMed ID: 31314619
    [No Abstract]   [Full Text] [Related]  

  • 7. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.
    Cohen AT; Harrington R; Goldhaber SZ; Hull R; Gibson CM; Hernandez AF; Kitt MM; Lorenz TJ
    Am Heart J; 2014 Mar; 167(3):335-41. PubMed ID: 24576517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients.
    Cave B; Hough A; Dobesh PP
    Pharmacotherapy; 2018 Jun; 38(6):597-609. PubMed ID: 29543384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
    Miller KM; Brenner MJ
    Drugs; 2019 Feb; 79(3):291-302. PubMed ID: 30719631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
    Chi G; Gibson CM; Kalayci A; Cohen AT; Hernandez AF; Hull RD; Kahe F; Jafarizade M; Sharfaei S; Liu Y; Harrington RA; Goldhaber SZ
    Intensive Care Med; 2019 Apr; 45(4):477-487. PubMed ID: 30778649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective.
    Spyropoulos AC; Ageno W; Cohen AT; Gibson CM; Goldhaber SZ; Raskob G
    Thromb Haemost; 2020 Jun; 120(6):924-936. PubMed ID: 32492724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
    Escolar G; Díaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 Aug; 53(8):423-434. PubMed ID: 29119147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
    Gibson CM; Chi G; Halaby R; Korjian S; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Gold A; Bandman O; Harrington RA; Cohen AT;
    Circulation; 2017 Feb; 135(7):648-655. PubMed ID: 27881569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.
    Ageno W; Lopes RD; Yee MK; Hernandez A; Hull RD; Goldhaber SZ; Gibson CM; Cohen AT
    J Thromb Haemost; 2019 Dec; 17(12):2089-2098. PubMed ID: 31392827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
    Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
    Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
    Gibson CM; Halaby R; Korjian S; Daaboul Y; Arbetter DF; Yee MK; Goldhaber SZ; Hull R; Hernandez AF; Lu SP; Bandman O; Leeds JM; Gold A; Harrington RA; Cohen AT;
    Am Heart J; 2017 Mar; 185():93-100. PubMed ID: 28267480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients.
    Gibson CM; Nafee T; Yee MK; Chi G; Korjian S; Daaboul Y; AlKhalfan F; Kerneis M; Goldhaber SZ; Hull R; Hernandez AF; Cohen AT; Harrington RA
    Am Heart J; 2018 Apr; 198():84-90. PubMed ID: 29653652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Betrixaban in the prevention of venous thromboembolism in medically ill patients.
    Sylvester KW; Connors JM
    Future Cardiol; 2018 Nov; 14(6):455-470. PubMed ID: 30353749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
    Garland SG; DeRemer CE; Smith SM; Gums JG
    Ann Pharmacother; 2018 Jun; 52(6):554-561. PubMed ID: 29338293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Betrixaban for prevention of venous thromboembolism in acute medically ill patients.
    Beyer-Westendorf J; Verhamme P; Bauersachs R
    Eur Heart J Suppl; 2018 May; 20(Suppl E):E16-E22. PubMed ID: 29977165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.